IP Library Granted Patent US 7,959,930
Granted Patent B2
US 7,959,930 · App. 11/722,769 · Granted Jun 14, 2011

Rescue of influenza virus

Assignee: Abbott Biologicals B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,959,930
App. No.
11/722,769
Granted
Jun 14, 2011
Kind
B2
Abstract

The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. The invention provides a nucleic acid comprising an influenza gene segment and a bacteriophage polymerase promotor or a complementary strand of said nucleic acid, and a cell comprising such a nucleic acid capable of producing desired influenza virus. Furthermore, the invention provides a composition comprising a cell or material derived from a cell according to the invention and a virus or material derived from a viral particle according to the invention.

Claims (18)

1. A method for producing a replicative influenza virus particle without the use of helper virus, comprising:

(a) transfecting a cell with at least one nucleic acid, wherein said nucleic acid is chosen from:

(1) an influenza gene segment and a bacteriophage polymerase promoter; and

(2) a complement of an influenza gene segment and a bacteriophage polymerase promoter; and

(b) culturing the transfected cell wherein said cell further comprises a bacteriophage polymerase.

2. The method according to claim 1 , wherein said at least one nucleic acid comprises at least one additional guanine residue next to the bacteriophage polymerase promoter.

3. The method according to claim 2 , wherein said at least one nucleic acid comprises at least two additional guanine residues next to the bacteriophage polymerase promoter.

4. The method according to claim 1 , wherein said at least one nucleic acid lacks a bacteriophage polymerase terminator.

5. The method according to claim 1 , wherein said bacteriophage polymerase promoter comprises a T7 polymerase promoter.

6. The method according to claim 1 , wherein said cell is transfected with at least seven or eight nucleic acids used in said method.

7. The method according to claim 1 , wherein said cell is transfected with a multi-plasmid system.

8. The method according to claim 7 , wherein the multi-plasmid system comprises twelve unidirectional plasmids expressing eight influenza vRNA nucleic acids, the influenza nucleoprotein, and polymerase proteins PA, PB1, and PB2.

9. The method according to claim 1 , wherein at least one said nucleic acid comprises an influenza gene segment that is derived from an influenza virus that is recommended by the World Health Organisation for vaccine purposes.

10. The method according to claim 1 , wherein at least one said nucleic acid comprises an influenza A gene segment.

11. The method according to claim 1 , wherein said bacteriophage polymerase further comprises a nuclear localization signal.

12. The method according to claim 11 , wherein said bacteriophage polymerase is T7 polymerase.

13. The method according to claim 1 , wherein said cell comprises a non-primate cell.

14. The method according to claim 13 , wherein said cell is chosen from an MDCK cell and a CEF cell.

Assignments (3)
CHANGE OF NAME Recorded Mar 9, 2011
From: SOLVAY BIOLOGICALS B.V.
To: ABBOTT BIOLOGICALS B.V.
Reel/Frame 025927/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2008
From: SOLVAY PHARMACEUTICALS B.V.
To: SOLVAY BIOLOGICALS B.V.
Reel/Frame 021499/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 25, 2007
From: DE WIT, EMMIE; SPORONKEN, MONIQUE I.J.; FOUCHIER, RON A.M.; OSTERHAUS, ALBERT D.M.E.
To: SOLVAY PHARMACEUTICALS B.V.; ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM
Reel/Frame 019473/0182 →
Priority Claims (1)
EP 04078527 · Dec 24, 2004 · regional
Continuity (2)
Provisional Application 60641003 · Jan 4, 2005
Related Publication 20080050401A1 · Feb 28, 2008